Overview
Skip to main content Published: Oct 31, 202 REDWOD CITY, Calif., Oct. 31, 202 (GLOBE NEWSWIRE) - Biomeafusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent smal molecules to treat and improve the lives of patients with geneticaly defined cancers and metabolic diseases, today anounced the dosing of the first patient with type 2 diabetes in the Phase I portion of COVALENT-1, a Phase I/I clinical trial underway in Canada.
Key Information
Biomea has completed the Phase I portion of the trial in healthy volunters.“With the dosing of our first patient with BMF-219, we have reached an important milestone for the nearly 50 milion patients worldwide with type 2 diabetes. We are pursuing BMF-219 with the aim to cure this disease. Beta cel preservation, reactivation and regeneration are the core components in providing diabetes patients with long term benefit,” stated Thomas Butler, Biomea Fusion’s Chief Executive Oficer and Chairman of the Board.
“The burden of diabetes is rapidly increasing, and we are faced with a global unmet ned for treatments with novel mechanisms of action. With BMF-219, a potentialy first-in-clas, covalent menin inhibitor, we are aiming to adres and reverse the rot cause of this epidemic.”Mr. Butler continued, “We leveraged an oportunity to begin clinical development earlier by initiating the COVALENT-1 study in Canada.
With the completion of the Phase I portion in healthy volunters, we have now swiftly progresed to dosing type 2 diabetes patients in the Phase I. In the meantime, we have ben in active discusions with the FDA and plan to file an IND before the end of the year. We expect to report initial Phase I data in the first half of 2023.”Rohit N.
Summary
Kulkarni MD, PhD, Senior Investigator and Margaret A Congleton Profesor; Section Head, Islet Cel and Regenerative Biology; and Profesor of Medicine, Harvard Medical Schol, comented: “Based on the promi